These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7530390)

  • 1. Identification of two independent neutralization domains on the VP4 trypsin cleavage products VP5* and VP8* of human rotavirus ST3.
    Padilla-Noriega L; Dunn SJ; López S; Greenberg HB; Arias CF
    Virology; 1995 Jan; 206(1):148-54. PubMed ID: 7530390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serologic analysis of human rotavirus serotypes P1A and P2 by using monoclonal antibodies.
    Padilla-Noriega L; Werner-Eckert R; Mackow ER; Gorziglia M; Larralde G; Taniguchi K; Greenberg HB
    J Clin Microbiol; 1993 Mar; 31(3):622-8. PubMed ID: 7681440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Location of intrachain disulfide bonds in the VP5* and VP8* trypsin cleavage fragments of the rhesus rotavirus spike protein VP4.
    Patton JT; Hua J; Mansell EA
    J Virol; 1993 Aug; 67(8):4848-55. PubMed ID: 8392619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies to the trypsin cleavage peptide VP8 neutralize rotavirus by inhibiting binding of virions to target cells in culture.
    Ruggeri FM; Greenberg HB
    J Virol; 1991 May; 65(5):2211-9. PubMed ID: 1850007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human rotavirus VP4 contains strain-specific, serotype-specific and cross-reactive neutralization sites.
    Kirkwood CD; Bishop RF; Coulson BS
    Arch Virol; 1996; 141(3-4):587-600. PubMed ID: 8645097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity, antigenicity, and protection efficacy of baculovirus expressed VP4 trypsin cleavage products, VP5(1)* and VP8* from rhesus rotavirus.
    Dunn SJ; Fiore L; Werner RL; Cross TL; Broome RL; Ruggeri FM; Greenberg HB
    Arch Virol; 1995; 140(11):1969-78. PubMed ID: 7503695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral immune responses to VP4 and its cleavage products VP5* and VP8* in infants vaccinated with rhesus rotavirus.
    Padilla-Noriega L; Fiore L; Rennels MB; Losonsky GA; Mackow ER; Greenberg HB
    J Clin Microbiol; 1992 Jun; 30(6):1392-7. PubMed ID: 1320626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of operationally overlapping and independent cross-reactive neutralization regions on human rotavirus VP4.
    Kobayashi N; Taniguchi K; Urasawa S
    J Gen Virol; 1990 Nov; 71 ( Pt 11)():2615-23. PubMed ID: 1701477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The VP5 domain of VP4 can mediate attachment of rotaviruses to cells.
    Zárate S; Espinosa R; Romero P; Méndez E; Arias CF; López S
    J Virol; 2000 Jan; 74(2):593-9. PubMed ID: 10623720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution of conserved and specific epitopes on the VP8 subunit of rotavirus VP4.
    Larralde G; Gorziglia M
    J Virol; 1992 Dec; 66(12):7438-43. PubMed ID: 1279204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Localization of membrane permeabilization and receptor binding sites on the VP4 hemagglutinin of rotavirus: implications for cell entry.
    Tihova M; Dryden KA; Bellamy AR; Greenberg HB; Yeager M
    J Mol Biol; 2001 Dec; 314(5):985-92. PubMed ID: 11743716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotype-specific epitope(s) present on the VP8 subunit of rotavirus VP4 protein.
    Larralde G; Li BG; Kapikian AZ; Gorziglia M
    J Virol; 1991 Jun; 65(6):3213-8. PubMed ID: 1709699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production and characterization of murine IgA monoclonal antibodies to the surface antigens of rhesus rotavirus.
    Giammarioli AM; Mackow ER; Fiore L; Greenberg HB; Ruggeri FM
    Virology; 1996 Nov; 225(1):97-110. PubMed ID: 8918537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The rhesus rotavirus gene encoding protein VP3: location of amino acids involved in homologous and heterologous rotavirus neutralization and identification of a putative fusion region.
    Mackow ER; Shaw RD; Matsui SM; Vo PT; Dang MN; Greenberg HB
    Proc Natl Acad Sci U S A; 1988 Feb; 85(3):645-9. PubMed ID: 2829198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies to rotavirus outer capsid glycoprotein VP7 neutralize infectivity by inhibiting virion decapsidation.
    Ludert JE; Ruiz MC; Hidalgo C; Liprandi F
    J Virol; 2002 Jul; 76(13):6643-51. PubMed ID: 12050377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteolysis of monomeric recombinant rotavirus VP4 yields an oligomeric VP5* core.
    Dormitzer PR; Greenberg HB; Harrison SC
    J Virol; 2001 Aug; 75(16):7339-50. PubMed ID: 11462006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigenic relationships among human rotaviruses as determined by outer capsid protein VP4.
    Gorziglia M; Larralde G; Kapikian AZ; Chanock RM
    Proc Natl Acad Sci U S A; 1990 Sep; 87(18):7155-9. PubMed ID: 1698292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trypsin activation pathway of rotavirus infectivity.
    Arias CF; Romero P; Alvarez V; López S
    J Virol; 1996 Sep; 70(9):5832-9. PubMed ID: 8709201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralization epitopes on rotavirus SA11 4fM outer capsid proteins.
    Gorziglia M; Larralde G; Ward RL
    J Virol; 1990 Sep; 64(9):4534-9. PubMed ID: 1696640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Localization of rotavirus VP4 neutralization epitopes involved in antibody-induced conformational changes of virus structure.
    Zhou YJ; Burns JW; Morita Y; Tanaka T; Estes MK
    J Virol; 1994 Jun; 68(6):3955-64. PubMed ID: 7514681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.